These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

191 related items for PubMed ID: 21095451

  • 21. Use of proliferation signal inhibitors in the management of post-transplant malignancies--clinical guidance.
    Campistol JM, Albanell J, Arns W, Boletis I, Dantal J, de Fijter JW, Mortensen SA, Neumayer HH, Øyen O, Pascual J, Pohanka E, Schena FP, Serón D, Sparacino V, Chapman JR.
    Nephrol Dial Transplant; 2007 May; 22 Suppl 1():i36-41. PubMed ID: 17456617
    [Abstract] [Full Text] [Related]

  • 22. Comparison of the effects of angiotensin receptor antagonist, angiotensin converting enzyme inhibitor, and their combination on regression of left ventricular hypertrophy of diabetes type 2 patients on recent onset hemodialysis therapy.
    Suzuki H, Kanno Y, Kaneko K, Kaneko M, Kotaki S, Mimura T, Takane H.
    Ther Apher Dial; 2004 Aug; 8(4):320-7. PubMed ID: 15274684
    [Abstract] [Full Text] [Related]

  • 23.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 24. Long-term maintenance therapy with calcineurin inhibitors: an update.
    Campistol JM.
    Transplant Proc; 2010 Nov; 42(9 Suppl):S21-4. PubMed ID: 21095445
    [Abstract] [Full Text] [Related]

  • 25. Angiotensin-converting enzyme inhibitors and effects on left ventricular hypertrophy.
    Dahlöf B.
    Blood Press Suppl; 1994 Nov; 2():35-40. PubMed ID: 8061844
    [Abstract] [Full Text] [Related]

  • 26. Conversion from calcineurin inhibitors to sirolimus in kidney transplant recipients: a retrospective cohort study.
    Cardinal H, Froidure A, Dandavino R, Daloze P, Hébert MJ, Colette S, Boucher A.
    Transplant Proc; 2009 Oct; 41(8):3308-10. PubMed ID: 19857737
    [Abstract] [Full Text] [Related]

  • 27. mTOR inhibition and erythropoiesis: microcytosis or anaemia?
    Diekmann F, Rovira J, Diaz-Ricart M, Arellano EM, Vodenik B, Jou JM, Vives-Corrons JL, Escolar G, Campistol JM.
    Nephrol Dial Transplant; 2012 Feb; 27(2):537-41. PubMed ID: 21785038
    [Abstract] [Full Text] [Related]

  • 28. A study of the relationships between angiotensin- converting enzyme gene, chymase gene polymorphisms, pharmacological treatment with ACE inhibitor and regression of left ventricular hypertrophy in essential hypertension patients treated with benazepril.
    He H, Li LM, Cao WH, Sun NL, Liu MZ, Hu YH.
    Ann Hum Biol; 2005 Feb; 32(1):30-43. PubMed ID: 15788353
    [Abstract] [Full Text] [Related]

  • 29. Efficacy of conversion to sirolimus in posttransplantation Kaposi's sarcoma.
    Gutiérrez-Dalmau A, Sánchez-Fructuoso A, Sanz-Guajardo A, Mazuecos A, Franco A, Rial MC, Iranzo P, Torregrosa JV, Oppenheimer F, Campistol JM.
    Transplant Proc; 2005 Nov; 37(9):3836-8. PubMed ID: 16386556
    [Abstract] [Full Text] [Related]

  • 30. Conversion from calcineurin inhibitors to sirolimus maintenance therapy in renal allograft recipients: 24-month efficacy and safety results from the CONVERT trial.
    Schena FP, Pascoe MD, Alberu J, del Carmen Rial M, Oberbauer R, Brennan DC, Campistol JM, Racusen L, Polinsky MS, Goldberg-Alberts R, Li H, Scarola J, Neylan JF, Sirolimus CONVERT Trial Study Group.
    Transplantation; 2009 Jan 27; 87(2):233-42. PubMed ID: 19155978
    [Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32. Comparison of sirolimus and everolimus in their effects on blood lipid profiles and haematological parameters in heart transplant recipients.
    Tenderich G, Fuchs U, Zittermann A, Muckelbauer R, Berthold HK, Koerfer R.
    Clin Transplant; 2007 Jan 27; 21(4):536-43. PubMed ID: 17645716
    [Abstract] [Full Text] [Related]

  • 33. Long-term results in renal transplant patients with allograft dysfunction after switching from calcineurin inhibitors to sirolimus.
    Bumbea V, Kamar N, Ribes D, Esposito L, Modesto A, Guitard J, Nasou G, Durand D, Rostaing L.
    Nephrol Dial Transplant; 2005 Nov 27; 20(11):2517-23. PubMed ID: 15985508
    [Abstract] [Full Text] [Related]

  • 34. Sirolimus in cardiac transplantation: use as a primary immunosuppressant in calcineurin inhibitor-induced nephrotoxicity.
    Kushwaha SS, Khalpey Z, Frantz RP, Rodeheffer RJ, Clavell AL, Daly RC, McGregor CG, Edwards BS.
    J Heart Lung Transplant; 2005 Dec 27; 24(12):2129-36. PubMed ID: 16364861
    [Abstract] [Full Text] [Related]

  • 35. An open-label, pilot study evaluating the safety and efficacy of converting from calcineurin inhibitors to sirolimus in established renal allograft recipients with moderate renal insufficiency.
    Peddi VR, Jensik S, Pescovitz M, Pirsch J, Adler SH, Thistlethwaite JR, Vincenti F, Cohen DJ.
    Clin Transplant; 2005 Feb 27; 19(1):130-6. PubMed ID: 15659146
    [Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38. Kaposi's sarcoma in renal transplant recipients--the impact of proliferation signal inhibitors.
    Campistol JM, Schena FP.
    Nephrol Dial Transplant; 2007 May 27; 22 Suppl 1():i17-22. PubMed ID: 17456614
    [Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 10.